Download
s00277-021-04482-3.pdf 328,26KB
WeightNameValue
1000 Titel
  • Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy
1000 Autor/in
  1. Ballo, Olivier |
  2. Eladly, Fagr |
  3. Büttner, Stefan |
  4. Stratmann, Jan Alexander |
  5. Rudolf, Sarah |
  6. Brunnberg, Uta |
  7. Kreisel, Eva-Maria |
  8. Steffen, Björn |
  9. Wagner, Sebastian |
  10. Finkelmeier, Fabian |
  11. Serve, Hubert |
  12. Brandts, Christian H. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-03-11
1000 Erschienen in
1000 Quellenangabe
  • 100(5):1159-1167
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00277-021-04482-3 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043920/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Acute kidney injury (AKI) complicates the clinical course of hospitalized patients by increasing need for intensive care treatment and mortality. There is only little data about its impact on AML patients undergoing intensive induction chemotherapy. In this study, we analyzed the incidence as well as risk factors for AKI development and its impact on the clinical course of AML patients undergoing induction chemotherapy. We retrospectively analyzed data from 401 AML patients undergoing induction chemotherapy between 2007 and 2019. AKI was defined and stratified according to KIDGO criteria by referring to a defined baseline serum creatinine measured on day 1 of induction chemotherapy. Seventy-two of 401 (18%) AML patients suffered from AKI during induction chemotherapy. AML patients with AKI had more days with fever (7 vs. 5, p = 0.028) and were more often treated on intensive care unit (45.8% vs. 10.6%, p < 0.001). AML patients with AKI had a significantly lower complete remission rate after induction chemotherapy and, with 402 days, a significantly shorter median overall survival (OS) (median OS for AML patients without AKI not reached). In this study, we demonstrate that the KIDGO classification allows mortality risk stratification for AML patients undergoing induction chemotherapy. Relatively mild AKI episodes have impact on the clinical course of these patients and can lead to chronic impairment of kidney function. Therefore, we recommend incorporating risk factors for AKI in decision-making considering nutrition, fluid management, as well as the choice of potentially nephrotoxic medication in order to decrease the incidence of AKI.
1000 Sacherschließung
lokal Adolescent [MeSH]
lokal Female [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Treatment Outcome [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Risk Factors [MeSH]
lokal Acute kidney failure
lokal Intensive care treatment
lokal Leukemia, Myeloid, Acute/complications [MeSH]
lokal Induction Chemotherapy/adverse effects [MeSH]
lokal Induction chemotherapy
lokal Original Article
lokal Acute myeloid leukemia
lokal Survival
lokal Male [MeSH]
lokal Young Adult [MeSH]
lokal Acute Kidney Injury/etiology [MeSH]
lokal Leukemia, Myeloid, Acute/drug therapy [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-1634-1988|https://frl.publisso.de/adhoc/uri/RWxhZGx5LCBGYWdy|https://frl.publisso.de/adhoc/uri/QsO8dHRuZXIsIFN0ZWZhbg==|https://frl.publisso.de/adhoc/uri/U3RyYXRtYW5uLCBKYW4gQWxleGFuZGVy|https://frl.publisso.de/adhoc/uri/UnVkb2xmLCBTYXJhaA==|https://frl.publisso.de/adhoc/uri/QnJ1bm5iZXJnLCBVdGE=|https://frl.publisso.de/adhoc/uri/S3JlaXNlbCwgRXZhLU1hcmlh|https://frl.publisso.de/adhoc/uri/U3RlZmZlbiwgQmrDtnJu|https://frl.publisso.de/adhoc/uri/V2FnbmVyLCBTZWJhc3RpYW4=|https://frl.publisso.de/adhoc/uri/Rmlua2VsbWVpZXIsIEZhYmlhbg==|https://frl.publisso.de/adhoc/uri/U2VydmUsIEh1YmVydA==|https://frl.publisso.de/adhoc/uri/QnJhbmR0cywgQ2hyaXN0aWFuIEgu
1000 Hinweis
  • DeepGreen-ID: 11ebc17084134d6c9f4098383e612489 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6447825.rdf
1000 Erstellt am 2023-05-03T16:32:45.568+0200
1000 Erstellt von 322
1000 beschreibt frl:6447825
1000 Zuletzt bearbeitet 2023-10-20T21:22:59.592+0200
1000 Objekt bearb. Fri Oct 20 21:22:59 CEST 2023
1000 Vgl. frl:6447825
1000 Oai Id
  1. oai:frl.publisso.de:frl:6447825 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source